GLP-1 and Dietary Influences: Fat, Protein, and Eating Patterns

GLP-1 is a hormone made in the gut that signals satiety to the brain, and it is the pathway targeted by drugs such as semaglutide and tirzepatide. Because the hormone is released in response to eating, what a person eats can influence the same system the medications act on. The relationship runs in both directions: diet can engage this pathway naturally, and the drugs change how people eat, which in turn affects muscle, nutrition, and what happens if treatment stops. This article draws on several expert discussions and cited studies to examine those dietary influences, with attention to where the evidence is limited.

Created with AI

In a conversation on The Proof with Simon Hill, a clinician and researcher described GLP-1 receptor agonists as doing more than suppressing appetite. In her account, they quiet what she calls "food noise," the constant background pull toward hyperpalatable, heavily marketed foods. Patients, she said, often report that for the first time food is not their main thought through the day.

She explained that GLP-1 and related peptides are produced in the gut and signal the hypothalamus, the brain region that governs food reward and food-seeking. According to her, the hypothalamus is also where genetic differences in appetite regulation are most pronounced. She pointed to intergenerational epigenetic effects, including leptin resistance during pregnancy, as a factor that can rewire offspring toward stronger food-seeking. On this view, attributing weight to willpower alone overlooks the biology.

Two implications follow for diet. First, the same dietary advice is unlikely to work equally well across a population, because food noise varies significantly between individuals. Second, she framed the drugs as opening a window of opportunity: with the biological pull reduced, patients can make deliberate food choices instead of reacting to constant cravings. She also noted that the drugs reduce desire for alcohol and tobacco in a significant proportion of patients, which suggests the mechanism extends beyond food-specific appetite suppression.

Created with AI

Ben Azadi reviewed one of the more concrete examples of food triggering gut hormones. He described a 2015 randomized crossover trial in the American Journal of Clinical Nutrition in which 12 healthy men ate carrots alone or carrots with 19 grams of olive oil. According to his account, the olive oil meal triggered release of GLP-1, PYY, CCK, and neurotensin, while plain carrots did not.

The proposed mechanism is that digestive enzymes cleave olive oil into a compound called 2-oleoylglycerol (2-OG). This compound binds to the GPR119 receptor in the gut lining, and activation of that receptor causes intestinal L-cells to release GLP-1. In Azadi's telling, a second route runs through oleic acid, the main fat in olive oil (61 to 81% of its content). In the small intestine, oleic acid is converted to a lipid messenger called OEA (oleoylethanolamide), which binds to PPAR-alpha, described as a master switch for fat metabolism. He reported that a study exposing fat cells to OEA confirmed fat release (lipolysis), and that the effect disappeared when the PPAR-alpha receptor was deleted in mice.

These findings deserve measured interpretation. The human trial as described involved 12 healthy men and measured hormone release after a single meal. The excerpt does not report long-term weight outcomes, so it does not show that olive oil produces effects comparable to GLP-1 medications, despite comparisons of that kind in popular discussion. The mouse work, similarly, shows a mechanism in animals rather than a clinical result in people.

Created with AI

Azadi also discussed oleocanthal, a polyphenol produced during the pressing of olives. He described a 2005 Nature paper, "Ibuprofen-Like Activity in Extra Virgin Olive Oil," showing that oleocanthal inhibits COX-1 and COX-2, the enzymes ibuprofen inhibits. He cited an estimate from that work that about 50 grams of high-quality olive oil delivers roughly 10% of an adult ibuprofen dose in anti-inflammatory effect. His reasoning was that inflammation contributes to insulin resistance in fat cells, so dampening it may interrupt part of the fat storage cycle. That is a proposed pathway rather than a demonstrated weight-loss effect.

The key caveat he raised is variability. According to Azadi, oleocanthal concentrations in commercial extra virgin olive oils range from around 700 mg/kg down to undetectable, because the polyphenol degrades with time, heat, and blending with cheaper oils. This is a reminder that the same food can differ greatly depending on how and where it is produced. Any benefit seen in a study using a particular oil may not carry over to a product of lower quality.

His practical suggestions for judging an oil were to sip a small amount and look for a peppery sting at the back of the throat, since no sting may indicate an oil that is old, refined, or adulterated. He also advised looking for a harvest date rather than a best-by date and favoring early harvest, cold-pressed, single-origin oils. These are his heuristics, not validated tests, and they should be read as such.

Created with AI

Thomas DeLauer argued that hunger is driven less by calorie deficit than by protein deficit. He drew on the protein leverage hypothesis, from an analysis in Obesity Reviews spanning multiple species, which proposes that appetite is calibrated to a protein target. When the target is not met, hunger persists regardless of total calories, which can drive overeating of carbohydrates and fat.

DeLauer cited an American Journal of Clinical Nutrition study in which raising protein from 15% to 30% of total calories led participants to spontaneously reduce intake by around 440 calories per day. In his reading, this means concentrated protein early in the day may reach the satiety target sooner and lower total intake without conscious restriction. He compared this to GLP-1 drugs, which he said act on the same satiety pathway that protein engages naturally. The comparison is conceptual; the excerpt does not claim that dietary protein matches the magnitude of drug effects.

His suggested framework included a protein intake of 1.3 to 2 g per kilogram of body weight per day, with 1.3 g/kg treated as a floor, and frontloading 30 to 50% of daily protein into the first meal. He favored nutrient-dense, complete sources, giving examples such as eggs with ground beef, sardines with beef, or Greek yogurt with whey protein. He also advised against keeping cooked ground beef longer than three days because of histamine buildup. These figures reflect his approach, and individual needs vary with age, health status, and medical advice.

Created with AI

A recurring concern in these discussions is that GLP-1 drugs can reduce protein intake along with total intake. According to Dr. Michael Diamonds, many users cut protein by half or more because appetite is so strongly suppressed. He said that a meaningful share of the weight lost under these conditions can be muscle rather than fat. DeLauer made a related point, noting that GLP-1 drugs can drive significant muscle loss alongside fat loss, whereas high protein intake combined with resistance training can preserve or even build muscle during severe caloric restriction. He referenced an American Journal of Clinical Nutrition study in which participants on an 800-calorie-per-day deficit who resistance trained still increased muscle fiber size.

The practical message in both accounts is that eating less does not remove the need to eat deliberately. When the drug quiets hunger signals, protein targets may need to be met on purpose, which is a different dynamic from the spontaneous satiety that protein produces without medication. Neither speaker presented this as a substitute for individualized medical guidance, and the evidence cited comes from specific studies with their own populations and conditions.

One related clinical detail concerns the oral form of semaglutide. The obesity physician on The Proof described it as requiring 4 oz of water, standing for 30 minutes, and a 30-minute wait before eating, with expected weight loss around 14%. By contrast, he said orforglipron, a non-peptide GLP-1 agonist with expected weight loss around 11.5%, can be taken with food, coffee, or at any time. Whether a medication can be taken with food is a dietary consideration in its own right, though the choice between agents is driven mainly by patient phenotype, preference, and coverage in his account.

Created with AI

Dr. Michael Diamonds described a client, Sergio Gonzalez, as an illustration of what a transition off a GLP-1 drug can look like. Gonzalez, a 47-year-old executive, went from 113 kg at 37 to 39% body fat down to 78 kg at 12.4% body fat. Diamonds said that when the drug is stopped without new behavioral habits in place, two-thirds of users regain the weight. He described the mechanisms as slowed gastric emptying, persistent fullness, and reduced food noise, all of which disappear with the drug. This is one practitioner's account of a single client, not a controlled study, and the figures should be treated accordingly.

In Diamonds' description, the habits that replaced the drug effect began with protein: about 200 grams daily for Gonzalez, frontloaded at breakfast. Meals were sequenced with fiber first, then protein, then carbohydrates, to blunt insulin spikes. Diamonds also mentioned apple cider vinegar 15 to 20 minutes before meals to reduce the glucose response. For appetite cues he described hara hachi bu, the Okinawan practice of eating to 80% fullness, and a 20-minute rule of waiting after a meal before considering more food. The protein amount reflects one person's body size and goals and is not a general target.

Beyond food, Diamonds linked behavior to physique. Gonzalez reviewed 8 years of smartwatch data and found his best physique years corresponded with 15,000 to 18,000 daily steps. Sleep was also emphasized: stopping caffeine by noon, stopping liquids 2 hours before bed, and using blue light blocking glasses. Diamonds said the "fat coefficient," the ratio of fat to carbohydrate burned as fuel, increases with sleep quality. Gonzalez himself reported gas, bloating, and digestive discomfort during treatment, along with anxiety about stopping, and he tapered faster than the standard protocol, stopping before peak dose. Such rapid tapering is not presented as a model to follow.

Created with AI

The sources together suggest that diet and GLP-1 biology are linked, but they also show why firm generalizations are risky. The olive oil findings come from a small trial of healthy men and from animal work, and the polyphenol content of real products varies widely. The protein leverage evidence is drawn from population and feeding studies, and its translation into advice differs by person. The transition account rests on one client and on a practitioner's estimate of regain.

The clinician on The Proof added a biological reason for caution: because hypothalamic wiring differs between individuals, response to both drugs and dietary advice differs too. A strategy that quiets hunger in one person may do little for another, and this variation reflects structural differences rather than discipline. Food quality and regional production also matter, as the olive oil example illustrates.

For readers, the most defensible takeaway is that food can engage satiety signaling and that protein adequacy is a recurring concern during appetite suppression. Decisions about diet alongside GLP-1 medication, or about stopping treatment, are best made with a clinician who knows the individual's health history.

Created with AI

• According to a 2015 crossover trial described by Ben Azadi, olive oil with carrots triggered GLP-1, PYY, CCK, and neurotensin release in 12 healthy men, apparently via 2-OG and the GPR119 receptor; hormone release is not the same as demonstrated weight loss.
• Oleocanthal levels in commercial extra virgin olive oils reportedly range from around 700 mg/kg to undetectable, so product quality and production may substantially affect any benefit.
• Thomas DeLauer cites the protein leverage hypothesis and a study in which raising protein from 15% to 30% of calories coincided with about 440 fewer calories eaten per day, suggesting protein may influence satiety.
• Both DeLauer and Dr. Michael Diamonds raise concern that appetite suppression can cut protein intake and contribute to muscle loss, and they emphasize protein adequacy and resistance training.
• Diamonds reports that two-thirds of users regain weight after stopping a GLP-1 drug without new habits; his client example (protein, meal sequencing, steps, sleep) is a single case, not controlled evidence.
• A clinician on The Proof stresses that food noise and hypothalamic wiring vary between people, so identical dietary advice is unlikely to work equally for everyone.